Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L.Nobuyuki Katakami, Takashi Seto, Yoshiko Urata et al.|Journal of Clinical Oncology|2014Cited by 11
TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.Misako Nagasaka, Yuichiro Ohe, Shunichi Sugawara et al.|Journal of Clinical Oncology|2022Cited by 4